Trial Profile
Phase Ib, Open Label, Single Center Study of Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Anaplastic large cell lymphoma; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Lymphoproliferative disorders; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 20 Jan 2021 Status changed from recruiting to discontinued. Reason the study was stopped: due to low accrual.
- 15 Jun 2020 Status changed from suspended to recruiting.
- 20 Apr 2020 Status changed from recruiting to suspended.